何氏生髓方联合聚乙二醇化重组人粒细胞集落刺激因子防治肺腺癌患者化疗后骨髓抑制的临床效果研究

摘要 目的：探讨何氏生髓方联合聚乙二醇化重组人粒细胞集落刺激因子（PEG-rhG-CSF）防治肺腺癌患者化疗后骨髓抑制的临床效果。方法：选取广州中医药大学东莞医院2021年3月~2022年10月期间收治的100例肺腺癌患者作为研究对象，采用随机数字表法将患者分为对照组（n=50，PEG-rhG-CSF治疗）和观察组（n=50，何氏生髓方联合PEG-rhG-CSF治疗）。观察两组中医证候积分、T淋巴细胞亚群指标、外周血象和中性粒细胞减少发生率变化情况。结果：治疗4个周期后，观察组神疲乏力、胃纳差、食少纳差、少气懒言、自汗盗汗、腰膝酸软症状评分低于对照组（P<0.05）。治疗4个周期后，观察组CD3⁺、CD4⁺、CD4⁺/CD8⁺高于对照组；CD8⁺低于对照组（P<0.05）。治疗4个周期后，观察组白细胞计数（WBC）、血小板计数（PLT）、中性粒细胞计数（NEUT）、血红蛋白（Hb）高于对照组（P<0.05）。观察组中性粒细胞减少发生率低于对照组（P<0.05）。结论：何氏生髓方联合PEG-rhG-CSF防治肺腺癌患者化疗后骨髓抑制，可提高机体免疫力，改善临床症状和外周血象，降低中性粒细胞减少发生率。

Clinical Effect of He's Shengsui Recipe Combine with Polyethylene Glycol Recombinant Human Granulocyte Colony Stimulating Factor on Prevention and Treatment of Bone Marrow Suppression of Patients with Lung Adenocarcinoma after Chemotherapy

ABSTRACT Objective: To explore the clinical effect of He''s Shengsui Recipe combine with polyethylene glycol recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) on prevention and treatment of bone marrow suppression of patients with lung adenocarcinoma after chemotherapy. Methods: 100 patients with lung adenocarcinoma who were admitted to Dongguan Hospital of Guangzhou University of Traditional Chinese Medicine from March 2021 to October 2022 were selected as the research subjects, and patients were divided into control group (n=50, treated with PEG-rhG-CSF) and observation group (n=50, treated with He''s Shengsui Recipe combined with PEG-rhG-CSF) using the random number table method. The changes of traditional Chinese medicine syndrome scores, T lymphocyte subgroup indexes, peripheral blood figure, and incidence of neutropenia between the two groups were observed. Results: 4 cycles after treatment, the symptom scores of fatigue, gastric anorexia, loss of appetite, lack of breath and lazy words, spontaneous sweating and night sweating, lumbar and knee soreness and weakness of the observation group were lower than those of the control group (P<0.05). 4 cycles after treatment, The CD3⁺, CD4⁺, CD4⁺/CD8⁺ of the observation group were higher than those of the control group, and the CD8⁺ was lower than that of the control group (P<0.05). 4 cycles after treatment, the white blood cell counts (WBC), platelet counts (PLT), neutrophil counts (NEUT), hemoglobin (Hb) of the observation group were higher than those of the control group (P<0.05). The incidence of neutropenia of the observation group was lower than that of the control group (P<0.05). Conclusion: He''s Shengsui Recipe combine with PEG-rhG-CSF to prevent and treat bone marrow suppression of patients with lung adenocarcinoma after chemotherapy, which can enhance the body''s immune system, improve clinical symptoms and peripheral blood figure, reduce the incidence of neutropenia.